Abstract

The human gut microbiota is a complex ecosystem harboring thousands of microbial strains that play a crucial role in maintaining the overall well-being of its host. The composition of the gut microbiota varies with age from infancy to adulthood and is influenced by dietary habits, environment, and genetic disposition. Recent advances in culture-independent techniques and nucleic acid sequencing have improved our understanding of the diversity of the gut microbiota. The microbial species present in the gut release short-chain fatty acids (SCFAs), which have anti-inflammatory properties. The gut microbiota also plays a substantial role in modulating the host's immune system, promoting immune tolerance, and maintaining homeostasis. The impact of the gut microbiota on the health of the host is quite evident, as gut dysbiosis has been linked to various diseases, including metabolic disorders, autoimmune diseases, allergies, and inflammatory bowel diseases. The gut microbiota has bidirectional communication with the respiratory system, creating the gut-lung axis, which has been associated with different respiratory diseases. Therapeutic approaches targeting the gut microbiota, such as probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation (FMT), aim to restore microbial balance and promote the growth of beneficial strains in the gut. Nonetheless, gaining knowledge of the complex interactions between the gut microbiota and the host is necessary to develop personalized medicine approaches and microbiota-based therapies for various conditions. This review summarizes studies related to the gut-lung axis with particular emphasis on the role of the microbiota. Future research directions are also discussed.

MeSH

Lung, Fecal Microbiota Transplantation, Pulmonary Disease, Chronic Obstructive, Probiotics, Therapeutics, Asthma, Gastrointestinal Microbiome, Microbiota

Cited by

• Hydrogen Sulfide and Gut Microbiota: Their Synergistic Role in Modulating Sirtuin Activity and Potential Therapeutic Implications for Neurodegenerative Diseases. Pharmaceuticals (Basel), 2024
• Effect of Supplementation of Quercetagetin on the Antioxidant Function, Liver Mitochondrial Function and Gut Microbiota of Broilers at High Stocking Density. Animals (Basel), 2025
• Diagnostic and prognostic values of NSCLC patients with or without obstructive pneumonia after sleeve lobectomy. Front Cell Infect Microbiol, 2024
• Chronic obstructive pulmonary disease: in-depth analysis of microbiota association and innovative prevention and treatment approaches from the gut-lung axis perspective. Front Immunol, 2025
• Longitudinal alterations of gut mycobiota during 2 years after COVID-19 and its correlation with pulmonary sequela. Microbiol Spectr, 2025
• Metabolomics in Atrial Fibrillation: Unlocking Novel Biomarkers and Pathways for Diagnosis, Prognosis, and Personalized Treatment. J Clin Med, 2025
• Aging and Viral Respiratory Infections: Focus on Vitamin D and Microbiota. Biomed Res Int, 2026
• Optimizing Cancer Treatment Through Gut Microbiome Modulation. Cancers (Basel), 2025
• Gut-lung axis in allergic asthma: microbiota-driven immune dysregulation and therapeutic strategies. Front Pharmacol, 2025
• Gut microbiota and viral respiratory infections: microbial alterations, immune modulation, and impact on disease severity: a narrative review. Front Microbiol, 2025